UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS - Roma, Italy; Istituto di Radiologia, Università Cattolica del Sacro Cuore - Roma, Italy.
UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS - Roma, Italy.
Radiother Oncol. 2021 Jan;154:154-160. doi: 10.1016/j.radonc.2020.09.026. Epub 2020 Sep 20.
Optimal timing of surgery after neoadjuvant chemoradiotherapy (Nad-CRT) is still controversial in locally advanced rectal cancer (LARC). The primary goal of this study was to determine the best surgical interval (SI) to achieve the highest rate of pathological complete response (pCR) and secondly to evaluate the effect on survival outcomes according to the SI.
Patients data were extracted from the international randomized trials: Accord12/0405, EORTC22921, FFCD9203, CAO/ARO/AIO-94, CAO-ARO-AIO-04, INTERACT and TROG01.04. Inclusion criteria were: age≥ 18, cT3-T4 and cN0-2, no clinical evidence of distant metastasis at diagnosis, Nad-CRT followed by surgery. Pearson's Chi-squared test with Yates' continuity correction for categorical variables, the Mann-Whitney test for continuous variables, Mann-Kendall test, Kaplan-Meier curves with log-rank test, univariate and multivariate logistic regression model was used for data analysis.
3085 patients met the inclusion criteria. Overall, the pCR rate was 14% at a median SI of 6 weeks (range 1-31). The cumulative pCR rate increased significantly when SI lengthened, with 95% of pCR events within 10 weeks from Nad-CRT. At univariate and multivariate logistic regression analysis, lengthening of SI (p< 0.01), radiotherapy dose (p< 0.01), and the addition of oxaliplatin to Nad-CRT (p< 0.01) had a favorable impact on pCR. Furthermore, lengthening of SI was not impact on local recurrences, distance metastases, and overall survival.
This pooled analysis suggests that the best time to achieve pCR in LARC is at 10 weeks, considering that the lengthening of SI is not detrimental concerning survival outcomes.
新辅助放化疗(Nad-CRT)后手术的最佳时机在局部进展期直肠癌(LARC)中仍存在争议。本研究的主要目的是确定最佳手术间隔(SI),以实现最高的病理完全缓解(pCR)率,其次是根据 SI 评估对生存结果的影响。
从国际随机临床试验中提取患者数据:Accord12/0405、EORTC22921、FFCD9203、CAO/ARO/AIO-94、CAO-ARO-AIO-04、INTERACT 和 TROG01.04。纳入标准为:年龄≥18 岁,cT3-T4 和 cN0-2,诊断时无远处转移的临床证据,Nad-CRT 后行手术。采用 Pearson's Chi-squared 检验(带 Yates 连续性校正)进行分类变量,Mann-Whitney 检验进行连续变量,Mann-Kendall 检验,Kaplan-Meier 曲线和对数秩检验,单变量和多变量逻辑回归模型进行数据分析。
共纳入 3085 例患者。总体而言,中位 SI 为 6 周时 pCR 率为 14%(范围 1-31)。随着 SI 的延长,pCR 率显著增加,Nad-CRT 后 10 周内有 95%的 pCR 事件。在单变量和多变量逻辑回归分析中,SI 延长(p<0.01)、放疗剂量(p<0.01)和在 Nad-CRT 中添加奥沙利铂(p<0.01)对 pCR 有有利影响。此外,SI 延长对局部复发、远处转移和总生存无影响。
本汇总分析表明,考虑到 SI 延长对生存结果没有不利影响,在 LARC 中实现 pCR 的最佳时间为 10 周。